Stealth BioTherapeutics Looks Ahead To Phase III In Mitochondrial Disease

Stealth BioTherapeutics is planning Phase III trials on the back of positive Phase II data for its lead product elamipretide in the rare indication of mitochondrial dysfunction, a disease for which there no currently approved treatments.